The European Society for Medical Oncology (ESMO) Breast Cancer Conference was a hybrid meeting, held virtually, as well as in Berlin, Germany on the 3-5 May. This annual meeting delivered the latest updates in the breast cancer field.
View all videos

ESMO Breast 2022

03–05 May 2022 | Berlin, Germany

ESMO Breast 2022

03–05 May 2022 | Berlin, Germany
The European Society for Medical Oncology (ESMO) Breast Cancer Conference was a hybrid meeting, held virtually, as well as in Berlin, Germany on the 3-5 May. This annual meeting delivered the latest updates in the breast cancer field.
View all videos

Latest videos from ESMO Breast 2022

View all
1:30
The role of myeloid-derived suppressor cells in breast cancer
Céline Blaye • 4 May 2022
0:53
TUXEDO-1: T-DXd for patients with HER2-positive breast cancer and brain metastasis
Rupert Bartsch • 5 May 2022
2:46
ELEANOR: observing real-life extended adjuvant therapy with neratinib and concurrent use of CONKADO
Nadia Harbeck • 4 May 2022
1:23
Antibody-drug conjugates for the treatment of breast cancer
Paolo Tarantino • 3 May 2022

HR+

View all
0:46
Biological behaviour of HER2-low BC is dependent on HR expression
Maria Fernanda Mosele • 5 May 2022
1:26
MonarchE: investigating adjuvant abemacicilib for high-risk HR+ breast cancer
Paolo Tarantino • 3 May 2022
1:55
Investigating anthracycline, taxane and trastuzumab-based neoadjuvant chemotherapy in HER2+ eBC
Benedetta Conte • 5 May 2022
1:19
Gene expression assays to identify patients with breast cancer for neoadjuvant treatment
Gaia Griguolo • 3 May 2022

HER2+

View all
1:59
ADAPT: de-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel in HR-/HER2+ eBC
Nadia Harbeck • 4 May 2022
1:15
Is it time to reconsider the locoregional approach in HER2+ breast cancer?
Philip Poortmans • 3 May 2022
1:39
Treatment for HER2+ metastatic breast cancer
Rupert Bartsch • 5 May 2022
1:08
Findings indicate HER2-low and HER2-negative breast cancer are biology indistinct
Benedetta Conte • 5 May 2022

TNBC

View all
1:22
Immunological signatures to predict outcomes in patients with TNBC
Céline Blaye • 4 May 2022
1:30
KEYNOTE-355: HRQoL unaffected by the addition of pembrolizumab to chemotherapy for TNBC
Dave Cescon • 3 May 2022
1:26
The association of the HER2DX signatures with survival in TNBC
Benedetta Conte • 5 May 2022
1:24
BEGONIA: durvalumab + dato-DXd in advanced TNBC
Yeon Hee Park • 3 May 2022

Breast Cancer Podcasts

Trial updates from ESMO Breast Cancer 2022: TUXEDO-1, monarchE, KEYNOTE-355
Novel treatment approaches in HR+/HER2- breast cancer
The Breast Cancer Sessions: Highlights from SABCS 2021
Updates on HER2-positive breast cancer

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals